PMID: 9194023May 1, 1997Paper

Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases

Journal of Psychosomatic Research
A N SinghJ Catalan

Abstract

We describe a consecutive series of 21 patients with HIV or AIDS who received risperidone for psychotic disorders. Of these, 13 became symptom-free, 7 showed substantial improvement, and 1 had no response. Most responded to low doses of risperidone (mean maximum dose 3.3 mg) and needed only a short course of treatment (mean 6.4 weeks). The 12 manic patients did particularly well: 9 became symptom-free and the mean Young mania rating scale fell from 28.36 to 3.91. No serious adverse effects were reported. Three patients became drowsy and two experienced drooling, but these resolved after dose reductions or at the end of treatment. No adverse hematological effects were observed. We suggest that risperidone may be the treatment of choice for patients with HIV-related psychotic disorders.

References

Oct 1, 1991·The Journal of Nervous and Mental Disease·S A Cooper, R A Collacott
Aug 1, 1991·The American Journal of Psychiatry·K KieburtzE D Caine
Aug 1, 1990·Psychological Medicine·M Maj
Aug 8, 1987·Lancet·H Edelstein, R T Knight
Aug 8, 1987·Lancet·M Maccario, D W Scharre
Dec 28, 1995·The New England Journal of Medicine·W J Fessel
Jan 1, 1994·Progress in Neuro-psychopharmacology & Biological Psychiatry·K HeinrichH Hruschka
Oct 8, 1994·Lancet·A N Singh, J Catalan
Feb 1, 1994·The American Journal of Psychiatry·D D SewellI Grant
Feb 1, 1993·The American Journal of Psychiatry·C G LyketsosG J Treisman
Jan 1, 1995·Journal of Psychopharmacology·H J ScurlockJ Catalan

❮ Previous
Next ❯

Citations

Jan 11, 2007·Wiener medizinische Wochenschrift·Hans-Bernd Rothenhäusler
May 11, 2002·Current Psychiatry Reports·Jordan Klesmer, Ruxandra Badescu
Apr 13, 2004·AIDS·Christian R DolderDilip V Jeste
Nov 1, 2002·Clinical Neuropharmacology·Francisco JoverJaime Merino
Feb 24, 2001·International Clinical Psychopharmacology·I Schweitzer
May 31, 2012·Journal of Neurovirology·Crystal C Watkins, Glenn J Treisman
Jul 4, 2006·General Hospital Psychiatry·Okan TaycanMine Ozmen
Aug 2, 2003·Biological Psychiatry·Dean G CruessJohn M Petitto
Jul 14, 2000·Current Medical Research and Opinion·B Green
Oct 22, 2008·Critical Care Clinics·Stephen J Ferrando, Zachary Freyberg
Mar 27, 2002·The Psychiatric Clinics of North America·Michael J Robinson, Roula B Qaqish
Aug 9, 2005·Biological Psychiatry·Dwight L EvansWilliam J Valvo
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·A GonzalezI Everall
Jun 4, 2008·Psychosomatic Medicine·Martin J Repetto, John M Petitto
Jul 14, 2001·The British Journal of Psychiatry. Supplement·J Cookson
Feb 28, 2003·Psychopharmacology·Paolo BrambillaJair C Soares

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
G Lera, J Zirulnik
International Journal of Psychiatry in Medicine
R S el-Mallakh
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
D D SewellI Grant
© 2021 Meta ULC. All rights reserved